1 unread notifications
Invited byLada Nuzhna

Sacha Schermerhorn is the founder and CEO of Babylon Biosciences, where he is building an AI-enabled drug-development portfolio for Alzheimer’s disease. A former neuroscience researcher and Lolly co-founder, he has published work on Alzheimer’s pathology and sensory decision coding.

Unclaimed profile

Sacha Schermerhorn is the founder and CEO of Babylon Biosciences, where he is building an AI-enabled drug-development portfolio for Alzheimer’s disease. A former neuroscience researcher and Lolly co-founder, he has published work on Alzheimer’s pathology and sensory decision coding.

Career

Sacha Schermerhorn studied at New York University.

Founder and CEO at Babylon Biosciences from 2023 to Present

Cosigns Received

These Cosigners would work with Sacha anywhere

nature.com

Behaviorally relevant decision coding in primary somatosensory cortex neurons

Sacha co-authored this 2022 Nature Neuroscience study on how primary somatosensory cortex activity encodes decisions during tactile behavior.

Open ↗
actaneurocomms.biomedcentral.com

Secernin-1 is a novel phosphorylated tau binding protein

A 2019 co-authored study identifying a tau-binding protein associated with Alzheimer’s disease but not other tauopathies.

Open ↗

Sacha's Collections

Sacha's Lists

In these lists

Cosigns Given